Semler Scientific, Inc. provided revenue guidance for the second quarter ending June 30, 2023 . The company expects its revenues for the second quarter ending June 30, 2023 will be the highest quarterly revenues in its history, driven by continued sales of QuantaFlo® to existing and new customers to test for peripheral arterial disease.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
32.18 USD | -3.52% |
|
-0.14% | -26.43% |
Jun. 07 | Sector Update: Health Care Stocks Mixed Pre-Bell Friday | MT |
Jun. 07 | Semler Scientific Files for $150 Million Mixed Shelf, $50 Million At-The-Market Equity Offering | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.43% | 236M | |
+75.69% | 12.57B | |
-29.04% | 6.9B | |
-9.82% | 5.69B | |
+5.81% | 5.04B | |
-17.70% | 4.69B | |
+14.80% | 4.18B | |
-18.25% | 3.86B | |
-23.07% | 2.97B | |
-1.98% | 1.99B |
- Stock Market
- Equities
- SMLR Stock
- News Semler Scientific, Inc.
- Semler Scientific, Inc. Provides Revenue Guidance for the Second Quarter Ending June 30, 2023